Focus: Jasper Therapeutics is a public biotech company specializing in humanized monoclonal antibodies across oncology, dermatology, respiratory, and ophthalmology. The company operates as a pre-revenue clinical-stage biotech with a focused pipeline and limited scale.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Jasper is a speculative early-stage play suited only for risk-tolerant candidates betting on mAb platform validation; limited hiring and precarious cash position present significant career continuity concerns.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Jasper Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Jasper Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats Q2 expectations but shares fall after results Yahoo Finance
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) Stock Titan
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE Stock Titan
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates scanx.trade
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition Quiver Quantitative
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview - TradingView
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo